![Galderma Announces Intention to Expand Manufacturing and Innovation Footprint in Asia-Pacific | Business Wire Galderma Announces Intention to Expand Manufacturing and Innovation Footprint in Asia-Pacific | Business Wire](https://mms.businesswire.com/media/20221012005570/en/1599610/5/DSC08984.jpg)
Galderma Announces Intention to Expand Manufacturing and Innovation Footprint in Asia-Pacific | Business Wire
![Galderma Announces Positive Phase 2 Results for its Proprietary Liquid Formulation of an Investigational Botulinum Toxin and Approval of New State-of-the-Art Manufacturing Facility Galderma Announces Positive Phase 2 Results for its Proprietary Liquid Formulation of an Investigational Botulinum Toxin and Approval of New State-of-the-Art Manufacturing Facility](https://mma.prnewswire.com/media/1006937/Galderma_New_Logo.jpg)
Galderma Announces Positive Phase 2 Results for its Proprietary Liquid Formulation of an Investigational Botulinum Toxin and Approval of New State-of-the-Art Manufacturing Facility
![Galderma navigates lip filler launch during COVID-19 with stay-at-home model shoots, telehealth materials | Fierce Pharma Galderma navigates lip filler launch during COVID-19 with stay-at-home model shoots, telehealth materials | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1589325302/RestylaneKysseImage.jpg?VersionId=UJ0yrSgYZN5SuKpvGwWNyaZ0LzUDPbU0)
Galderma navigates lip filler launch during COVID-19 with stay-at-home model shoots, telehealth materials | Fierce Pharma
![Galderma: Combined Use of Rosacea Therapies Ivermectin 1% Cream and Brimonidine 0.33% Gel Evaluated in MOSAIC Study Galderma: Combined Use of Rosacea Therapies Ivermectin 1% Cream and Brimonidine 0.33% Gel Evaluated in MOSAIC Study](http://mma.prnewswire.com/media/554005/Galderma_Logo.jpg?p=facebook)